Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;81(12):1134-1145.
doi: 10.1055/s-0043-1777729. Epub 2023 Dec 29.

Advances in diffuse glial tumors diagnosis

Affiliations
Review

Advances in diffuse glial tumors diagnosis

Luis Filipe de Souza Godoy et al. Arq Neuropsiquiatr. 2023 Dec.

Abstract

In recent decades, there have been significant advances in the diagnosis of diffuse gliomas, driven by the integration of novel technologies. These advancements have deepened our understanding of tumor oncogenesis, enabling a more refined stratification of the biological behavior of these neoplasms. This progress culminated in the fifth edition of the WHO classification of central nervous system (CNS) tumors in 2021. This comprehensive review article aims to elucidate these advances within a multidisciplinary framework, contextualized within the backdrop of the new classification. This article will explore morphologic pathology and molecular/genetics techniques (immunohistochemistry, genetic sequencing, and methylation profiling), which are pivotal in diagnosis, besides the correlation of structural neuroimaging radiophenotypes to pathology and genetics. It briefly reviews the usefulness of tractography and functional neuroimaging in surgical planning. Additionally, the article addresses the value of other functional imaging techniques such as perfusion MRI, spectroscopy, and nuclear medicine in distinguishing tumor progression from treatment-related changes. Furthermore, it discusses the advantages of evolving diagnostic techniques in classifying these tumors, as well as their limitations in terms of availability and utilization. Moreover, the expanding domains of data processing, artificial intelligence, radiomics, and radiogenomics hold great promise and may soon exert a substantial influence on glioma diagnosis. These innovative technologies have the potential to revolutionize our approach to these tumors. Ultimately, this review underscores the fundamental importance of multidisciplinary collaboration in employing recent diagnostic advancements, thereby hoping to translate them into improved quality of life and extended survival for glioma patients.

Nas últimas décadas, houve avanços significativos no diagnóstico de gliomas difusos, impulsionados pela integração de novas tecnologias. Esses avanços aprofundaram nossa compreensão da oncogênese tumoral, permitindo uma estratificação mais refinada do comportamento biológico dessas neoplasias. Esse progresso culminou na quinta edição da classificação da OMS de tumores do sistema nervoso central (SNC) em 2021. Esta revisão abrangente tem como objetivo elucidar esses avanços de forma multidisciplinar, no contexto da nova classificação. Este artigo irá explorar a patologia morfológica e as técnicas moleculares/genéticas (imuno-histoquímica, sequenciamento genético e perfil de metilação), que são fundamentais no diagnóstico, além da correlação dos radiofenótipos da neuroimagem estrutural com a patologia e a genética. Aborda sucintamente a utilidade da tractografia e da neuroimagem funcional no planejamento cirúrgico. Destacaremos o valor de outras técnicas de imagem funcional, como ressonância magnética de perfusão, espectroscopia e medicina nuclear, na distinção entre a progressão do tumor e as alterações relacionadas ao tratamento. Discutiremos as vantagens das diferentes técnicas de diagnóstico na classificação desses tumores, bem como suas limitações em termos de disponibilidade e utilização. Além disso, os crescentes avanços no processamento de dados, inteligência artificial, radiômica e radiogenômica têm grande potencial e podem em breve exercer uma influência substancial no diagnóstico de gliomas. Essas tecnologias inovadoras têm o potencial de revolucionar nossa abordagem a esses tumores. Em última análise, esta revisão destaca a importância fundamental da colaboração multidisciplinar na utilização dos recentes avanços diagnósticos, com a esperança de traduzi-los em uma melhor qualidade de vida e uma maior sobrevida.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest to declare.

Figures

Figure 1
Figure 1
Two examples of different glial neoplasms defined by molecular findings. The first case ( A-C ) is a hemispheric tumor from a 43-year-old male patient. The cells have typical astrocytic morphology ( A ), with immunohistochemistry positive for IDH1 R132H ( B ) and ATRX loss ( C ). These findings are consistent with astrocytoma, The second case ( D-F ) is a pontine tumor in a 8-year-old patient. Although morphology is also astrocytic ( D ), the loss of H3K27me3 expression ( E ) and positivity for H3K27M mutation ( F ) rendered this patient a “diffuse midline glioma, H3 K27-altered” diagnosis.
Figure 2
Figure 2
Low-grade adult-type gliomas. Astrocytoma, IDH-mutant in a 29-year-old woman ( A , B and C ). Axial T2( A ) shows a relatively homogenous hyperintense lesion on the right middle frontal gyrus. Axial FLAIR ( B ) shows a heterogeneous low signal intensity, except for a peripheral rim (arrows) of preserved hyperintensity (T2-FLAIR “mismatch” sign). Axial T1 post-gadolinium ( C ) shows no enhancement. Oligodendroglioma, IDH-mutant, 1p/19q co-deleted in a 58-year woman ( D , E , F and G ). Axial T2 ( D ) demonstrates a heterogeneous hyperintense lesion in the right frontal lobe, with indistinct margins and the sinuous wave-like intratumoral-wall sign, representing cortical thickening (arrows and dashed line) around a T2 heterogeneously hyperintense core. Axial FLAIR ( E ) demonstrates no significant signal suppression except for a small cyst (arrow). Axial T1 post-gadolinium ( F ) shows no significant lesion enhancement. Axial CT ( G ) shows a linear calcification within the lesion (arrow).
Figure 3
Figure 3
High-grade adult-type glioma. Common GBM presentation in a 52-year-old male ( A and B ). Axial FLAIR ( A ) shows a heterogeneous lesion involving the right parietal and occipital transition, with surrounding edema. Axial T1 post-gadolinium( B ) demonstrates thick, irregularly shaped enhancement with central necrosis. Uncommon GBM presentation in a 66-year-old female ( C , D , and E ). Axial FLAIR ( C ) shows an infiltrative lesion involving the right temporal lobe (arrows). Axial T1 post-gadolinium ( D ) shows no enhancement in the lesion (arrows). Axial DWI ( E ) demonstrates an area of restricted diffusion delineating the cortex (arrow). This patient presented with seizures and was initially treated for herpes encephalitis, but subsequent progression and pathology (not shown) confirmed a GBM. Grade 4 astrocytoma, IDH-mutant in a 34-year-old female ( F and G ). Axial T1 post-gadolinium ( F ) shows a left parietal lesion with contrast enhancement and necrosis (arrow), with a significant non-enhancing component (arrowheads). In the nonenhancing part of the lesion, FLAIR signal suppression is consistent with IDH mutation.
Figure 4
Figure 4
Pediatric type tumors. High grade. DMG in a 3-year-old boy ( A and B ). Axial T2 ( A ) shows an infiltrative lesion centered on ventral pons, extending anteriorly to “embrace” the basilar artery (arrow). Axial T1 post-gadolinium ( B ) shows ring enhancement at the right anterior portion of the tumor (arrow). Low Grade. Angiocentric glioma in a 17-year-old boy ( C and D ). Axial FLAIR ( C ) demonstrates a hyperintense lesion with cysts (arrow) on the left middle frontal and pre-central gyrus. Axial T1( D ) without gadolinium shows typical linear cortical hyperintensity (arrow). PLNTY in a 18-year-old girl ( E and F ). Axial CT ( E ) demonstrates a massively calcified lesion in the left occipital and temporal lobe transition (arrow). Axial T1 post-gadolinium ( F ) shows partial ring-like enhancement (arrow).
Figure 5
Figure 5
Neuroplasticity over 13 years. Axial T2 ( A ) shows an IDH-mutant astrocytoma in the right primary motor cortex (arrow). Axial FLAIR fused with fMRI ( B ) with left motor hand task shows BOLD signal in the expected location at the right pre-central gyrus, near the posterior and medial tumoral margin (arrow). Axial T2 ( C ) performed five months after near total resection demonstrated only slight hyperintensity at the medial border of the surgical cavity (arrows). Axial T2 ( D ), 13 years later, shows a progression of the astrocytoma, now infiltrating medially the pre-central gyrus, toward the hand motor knob area (arrow). At this time, fMRI ( E ) with left-hand motor activity shows little BOLD signal in the right pre-central gyrus (arrowhead) but a more extensive BOLD signal in left motor areas (arrow), indicating the recruitment of ipsilateral motor cortex due to neuroplasticity.

References

    1. Martin-Villalba A, Okuducu A F, von Deimling A. The evolution of our understanding on glioma. Brain Pathol. 2008;18(03):455–463. doi: 10.1111/j.1750-3639.2008.00136.x. - DOI - PMC - PubMed
    1. Board TWCoTE . 5th ed. International Agency for Research on Cancer (IARC); 2021. WHO classification of tumours series, 5th ed.; vol. 6. (WHO classification of tumours series, Vol. .).
    1. Brat D J, Aldape K, Colman H et al.cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(03):603–608. doi: 10.1007/s00401-020-02127-9. - DOI - PMC - PubMed
    1. Brat D J, Aldape K, Colman H et al.cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 2018;136(05):805–810. doi: 10.1007/s00401-018-1913-0. - DOI - PMC - PubMed
    1. Louis D N, Perry A, Wesseling P et al.The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncol. 2021;23(08):1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed

MeSH terms